Comparative Pharmacology
Head-to-head clinical analysis: BUTAZOLIDIN versus INDICLOR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: BUTAZOLIDIN versus INDICLOR.
BUTAZOLIDIN vs INDICLOR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis. Also has uricosuric effect at higher doses.
Alkylating agent that crosslinks DNA, inhibiting DNA replication and transcription.
Butazolidin (phenylbutazone) is typically administered orally at 100-200 mg 3 times daily with meals, not to exceed 600 mg/day. Initial loading dose of 400 mg may be given on day 1, followed by 300-400 mg/day in divided doses. Duration should be limited to 7-10 days.
INDICLOR is not a recognized drug; no standard dosing available.
None Documented
None Documented
Terminal half-life: 50-100 hours (prolonged in elderly or hepatic/renal impairment; accumulation risk evident within 5-7 days).
Terminal elimination half-life is 12 hours (range 10-15 hours) in patients with normal renal function; prolonged in renal impairment (up to 25 hours in severe cases).
Primarily renal: ~60% as unchanged drug and glucuronide conjugates; biliary/fecal: ~40% (enterohepatic circulation).
Primarily renal excretion (approximately 70% unchanged drug); biliary/fecal excretion accounts for about 10-15% as metabolites.
Category C
Category C
NSAID
NSAID